38 results
8-K
EX-10.1
snf2021 fdmh
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
ahisfdn
14 Feb 24
Other Events
4:11pm
8-K
EX-99.1
nkqarxz1 2xqxi
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
usx0q p9pibk
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-2.1
midzmh14u3vxcx183gn4
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-99.1
4ot p6j7dw
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K
8xdj567x3pf0h1ty5
15 Nov 23
Regulation FD Disclosure
6:03am
8-K
EX-99.1
2to 75j0lp
15 Nov 23
Regulation FD Disclosure
6:03am
424B3
5p4rhp
28 Aug 23
Prospectus supplement
9:10am
S-4/A
me0un
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
rc6uspfdx uzguy55k
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-99.1
cik0doy48hwh kgiu
5 Jul 23
Business combination disclosure
5:15pm